

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OP
*RECEIVED
FEB 6 2005
U.S. PATENT AND TRADEMARK OFFICE*
In re application of: Morishita et al.

Application No. 09/869,475

Filed: October 10, 2001

Confirmation No. 4309

For: GENE THERAPY FOR DIABETIC
ISCHEMIC DISEASE

Examiner: Brian A. Whiteman

Art Unit: 1635

Attorney Reference No. 6235-59221-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed February 3, 2005

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.


This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-59221-01
Application Number	09/869,475
Filing Date	October 10, 2001
First Named Inventor	Morishita
Art Unit	1635
Examiner Name	Brian A. Whiteman

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 98/19712 A1	05/14/1998	St. Elizabeth's Medical Center of Boston, Inc.
		WIPO	WO 98/51798 A1	11/19/1998	Imperial Cancer Research Technology Limited
		WIPO	WO 00/62798 A2	10/26/2000	St. Elizabeth's Medical Center of Boston, Inc.
		WIPO	WO 00/62798 A3	10/26/2000	St. Elizabeth's Medical Center of Boston, Inc.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.